Axel Hoos

Axel Hoos

Presidente presso
Cancer Research Institute
56 anni
Health Technology
Commercial Services
Health Services

Profilo

Axel Hoos was the founder of Imugene Ltd. (founded in 2013) and held the title of Independent Non-Executive Director.
He is currently the Co-Chairman at Cancer Research Institute, Director at Nextpoint Therapeutics, Inc. (since 2023), and Trustee at Albert B. Sabin Vaccine Institute, Inc. Dr. Hoos has previously served as the Chief Executive Officer & Director at Scorpion Therapeutics, Inc. (2021-2024), Senior Director-Clinical Development at Agenus, Inc. (2001-2005), Independent Director at TCR2 Therapeutics, Inc. (2020-2023), and Global Medical Lead-Immunology & Oncology at Bristol Myers Squibb Co. (2005-2011).
He has also held the position of Senior VP & Therapeutic Area Head-Oncology at GlaxoSmithKline Pharmaceuticals Ltd. Dr. Hoos obtained his doctorate degree from Ruprecht-Karls-Universität Heidelberg in 1997.

Posizioni attive di Axel Hoos

SocietàPosizioneInizio
Direttore/Membro del Consiglio -
Presidente -
Direttore/Membro del Consiglio 21/03/2023

Precedenti posizioni note di Axel Hoos

SocietàPosizioneFine
Amministratore Delegato 04/01/2024
TCR2 THERAPEUTICS INC. Direttore/Membro del Consiglio 01/06/2023
IMUGENE LIMITED Fondatore 19/11/2021
BRISTOL-MYERS SQUIBB COMPANY Corporate Officer/Principal 01/01/2011
AGENUS INC. Corporate Officer/Principal 01/01/2005
Vedi nel dettaglio l'esperienza di Axel Hoos

Formazione di Axel Hoos

Esperienze
Posizioni ricoperte

Attive

Inattive

Società nel listino

Aziende private

Relazioni

80

Relazioni di 1° grado

10

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Società collegate

Aziende private10

Health Technology

Health Technology

Commercial Services

Health Technology

Health Technology

Health Services

Consumer Services

Health Technology

Health Technology

Commercial Services